CIK 0001396814 · Large accelerated filer
Pacira BioSciences, Inc.
Sign in to watch- Ticker
- PCRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 510619477
- Phone
- 650-242-8052
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE, CA, 94005
- Former names
- Pacira Pharmaceuticals, Inc., PACIRA INC, Blue Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,539
- in 2 filings, $289K under 10b5-1 plans
Net −$288,539. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-02 | SLONIN JONATHAN Chief Medical Officer | Shares withheld for taxes 10b5-1 | −371 | $18.33 | $7K | 94,322.51 |
| 2025-01-02 | RIKER LAUREN Senior Vice President, Finance | Shares withheld for taxes | −159 | $18.33 | $3K | 37,916.34 |
| 2024-12-31 | GAUGLER DARYL Chief Operating Officer | Grant or award | +243.54 | $16.01 | $4K | 115,443.49 |
| 2024-12-13 | GAUGLER DARYL Chief Operating Officer | Sale 10b5-1 | −500 | $19.76 | $10K | 115,199.95 |
| 2024-11-04 | Cross Shawn Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2024-11-01 | Cross Shawn Chief Financial Officer | Grant or award | +75,000 | 75,000 | ||
| 2024-09-13 | GAUGLER DARYL Chief Operating Officer | Sale 10b5-1 | −500 | $12.86 | $6K | 115,699.95 |
| 2024-08-16 | BIGAL MARCELO Director | Purchase | +1,512 | $13.25 | $20K | 10,142 |
| 2024-08-16 | Brege Laura Director | Purchase | +1,000 | $12.81 | $13K | 17,552 |
| 2024-08-14 | YANG MICHAEL J. Director | Purchase | +2,000 | $12.90 | $26K | 7,230 |
| 2024-08-12 | Lee Frank D. Chief Executive Officer | Purchase | +8,264 | $12.10 | $100K | 107,784 |
| 2024-08-12 | BIGAL MARCELO Director | Purchase | +3,400 | $12.01 | $41K | 8,630 |
| 2024-08-12 | Froimson Mark Director | Purchase | +1,400 | $11.58 | $16K | 14,473 |
| 2024-08-12 | BIGAL MARCELO Director | Purchase | +3,400 | $12.01 | $41K | 8,630 |
| 2024-08-02 | SLONIN JONATHAN Chief Medical Officer | Sale 10b5-1 | −945 | $20.05 | $19K | 94,306.75 |
| 2024-08-01 | SLONIN JONATHAN Chief Medical Officer | Shares withheld for taxes 10b5-1 | −305 | $20.75 | $6K | 95,251.75 |
| 2024-07-02 | SLONIN JONATHAN Chief Medical Officer | Sale 10b5-1 | −2,836 | $28.25 | $80K | 95,556.75 |
| 2024-07-01 | SLONIN JONATHAN Chief Medical Officer | Shares withheld for taxes 10b5-1 | −914 | $28.46 | $26K | 98,392.75 |
| 2024-06-28 | GAUGLER DARYL Chief Operating Officer | Grant or award | +160.37 | $24.32 | $4K | 116,199.95 |
| 2024-06-28 | SLONIN JONATHAN Chief Medical Officer | Grant or award 10b5-1 | +437.27 | $24.32 | $11K | 99,306.75 |
Page 6 of 9 · 161 trades